Covid-19 vaccine: Oxford candidate safe, shows immune response in trial

The preliminary results of the phase 1-2 trial, published in The Lancet journal, involved 1,107 healthy adults, and found that the vaccine induced an immune response both via antibodies and T-cells

The early-stage human trial data has revealed that the Covid-19 vaccine candidate developed by AstraZeneca and Oxford University is safe and induces immune response, with mild side effects in some participants, which the scientists say can be treated with the commonly available pain medication paracetamol.

The preliminary results of the phase 1-2 trial, published in The Lancet journal, involved 1,107 healthy adults, and found that the vaccine induced an immune response both via antibodies and the T-cells of the immune system up to day 56 of the ongoing trial.

"The Phase I/II data for our coronavirus vaccine shows that the vaccine did